Anemia treatment and left ventricular hypertrophy in non-dialysis chronic kidney disease

被引：0

作者：

Robert NFoley ^{[1
]}

Peter AMcCullough ^{[2
]}

机构：

[1] Chronic Disease Research Group Minneapolis Medical Research Foundation,Minneapolis,Minnesota University of Minnesota,Minneapolis,MN,USA

[2] Department of Medicine Divisions of Cardiology,Nutrition,and Preventive Medicine,William Beaumont Hospital,Royal Oak,MI,USA

来源：

Journal of Geriatric Cardiology | 2005年 / 04期

关键词：

CKD; left; Anemia treatment and left ventricular hypertrophy in non-dialysis chronic kidney disease;

D O I：

暂无

中图分类号：

R692 [肾疾病];

学科分类号：

1002 ; 100210 ;

摘要：

<正>To this day, the target hemoglobin level that minimizes cardiovascular risk in chronic kidney disease (CKD) patients remains unclear. When one examines the many randomized trials of epoetin therapy in aggregate, enhanced quality of life provides the most cogent argument for hemoglobin levels above 110 g/L. It remains unclear whether treatment of anemia improves longevity, or even a surrogate marker (such as left ventricular [LV] mass index), especially when applied at earlier phases of CKD.

引用

页码：195 / 195

页数：1